|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S1
|
$48,687
|
$10,711
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S2
|
$85,299
|
$18,766
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S3
|
$47,040
|
$10,349
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
$356,264
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
|
(1/2) University of Guam/University of Hawaii Cancer Center Partnership
|
5U54CA143727-07
|
$1,275,740
|
$229,633
|
PALAFOX, NEAL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-07
|
$730,767
|
$321,537
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership
|
1U54CA221704-01A1
|
$1,050,067
|
|
OGUNWOBI, OLORUNSEUN
|
HUNTER COLLEGE
|
|
|
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
|
3R01CA227473-01S1
|
$293,469
|
|
HEROLD, KEVAN
|
YALE UNIVERSITY
|
|
|
(ACCSIS) Accelerating Colorectal Cancer Screening through Implementation Science in Appalachia
|
1UG3CA233282-01
|
$770,562
|
|
DIGNAN, MARK
|
UNIVERSITY OF KENTUCKY
|
|
|
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
|
1R01CA231291-01
|
$533,211
|
|
WELLSTEIN, ANTON
|
GEORGETOWN UNIVERSITY
|
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
1R01CA206025-01
|
$655,037
|
$655,037
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
3R01CA206025-03S1
|
$52,355
|
$52,355
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance
|
1R01CA231283-01
|
$501,220
|
|
LIPKIN, STEVEN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
|
(PQ1) The role of cell-to-cell variation in the penetrance of heritable mutant RAS hypodermal neoplasias
|
1R01CA219460-01A1
|
$397,573
|
|
MENDENHALL, ALEXANDER
|
UNIVERSITY OF WASHINGTON
|
|
|
(PQ11) Dietary strategies to enhance FOLFOX cancer therapies
|
1R21CA231255-01
|
$189,744
|
|
ROSENBERG, DANIEL
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
|
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
|
1R01CA231267-01
|
$460,814
|
|
FEHRENBACHER, JILL
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
|
1R01CA231325-01
|
$572,540
|
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
|
(PQ3) UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS
|
1R01CA230712-01
|
$633,992
|
|
JENKINS, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
|
(PQ4) - Tools for simultaneous disruption of multiple epigenetically silenced genes for studying their roles in tumorigenesis using ex vivo human and mouse colon organoid and in vivo mouse models
|
1R01CA230995-01
|
$374,578
|
|
EASWARAN, HARIHARAN
|
JOHNS HOPKINS UNIVERSITY
|
|
|
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression
|
1R01CA231112-01
|
$576,627
|
|
CHEN, SIDI
|
YALE UNIVERSITY
|
|
|
(PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivo
|
1R01CA231253-01
|
$471,700
|
|
WINSLOW, MONTE
|
STANFORD UNIVERSITY
|
|
|
(PQ4A) Metabolic Plasticity of Pre-Malignant Cells During Tumor Progression
|
3R01CA194461-04S1
|
$7,505
|
|
PARK, KWON-SIK
|
UNIVERSITY OF VIRGINIA
|
|
|
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma
|
1R01CA219850-01A1
|
$558,022
|
|
DANIAL, NIKA
|
DANA-FARBER CANCER INST
|
|
|
(PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
|
3R01CA208642-03S1
|
$71,387
|
|
SHACKELFORD, DAVID
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
(PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
|
3R01CA208642-03S2
|
$83,925
|
|
SHACKELFORD, DAVID
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
(PQ5) Informing anal neoplasia differences/similarities in HIV-serodiscordant individuals
|
3R21CA216830-02S1
|
$68,478
|
|
SHIRAMIZU, BRUCE
|
UNIVERSITY OF HAWAII AT MANOA
|
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
3R01CA205967-03S2
|
$230,366
|
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
|
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
|
1R01CA216101-01A1
|
$670,933
|
|
SHADEL, GERALD
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
|
|
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
|
1R01CA205632-01
|
$469,489
|
$469,489
|
RIEGEL, ANNA
|
GEORGETOWN UNIVERSITY
|
|
|
(PQ6) Radiogenomics of colorectal polyps to assess benign proliferative vs. premalignant states.
|
5R01CA220004-02
|
$698,964
|
|
GRADY, WILLIAM
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
|
1R01CA230848-01
|
$442,560
|
|
FU, LONING
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
|
1R01CA205101-01
|
$406,070
|
$406,070
|
SKALA, MELISSA
|
MORGRIDGE INSTITUTE FOR RESEARCH, INC.
|
|
|
(PQ8) BONE MARROW-ON-A-CHIP"":AN INVITRO 3D MODEL OF BREAST CANCER DORMANCY
|
1R21CA208519-01
|
$165,844
|
$165,844
|
GEORGE, STEVEN
|
WASHINGTON UNIVERSITY
|
|
|
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
|
1R01CA231295-01
|
$481,288
|
|
OSMAN, IMAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
|
(PQ9) A novel mechanism of paclitaxel-induced peripheral neuropathy and potential treatment
|
1R01CA208765-01
|
$351,874
|
$351,874
|
YANG, QING
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
|
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae
|
1R01CA208634-01
|
$560,277
|
$280,139
|
JURECIC, ROLAND
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
|
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer
|
1R01CA230854-01
|
$249,841
|
$249,841
|
JIN, JIAN
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
|
(PQ9) Dual Action RSK Inhibitor: Targeting Metastasis and Providing Cardioprotection
|
1R21CA208631-01
|
$251,120
|
$251,120
|
LANNIGAN, DEBORAH
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle
|
7R21CA205437-02
|
$152,333
|
$152,333
|
WANING, DAVID
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle.
|
1R21CA205437-01
|
$51,247
|
$51,247
|
WANING, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
|
1R01CA205255-01
|
$577,463
|
$577,463
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INST
|
|
|
(PQA-5) DNA methylation and cancer prevention: duration and intensity of exercise
|
4R01CA179963-04
|
$513,435
|
$513,435
|
BRYAN, ANGELA
|
UNIVERSITY OF COLORADO
|
|
|
(PQA1)Molecular mechanisms by which the diabetic drug metformin kills cancer cell
|
4R01CA180033-04
|
$295,065
|
$295,065
|
MISKIMINS, W
|
SANFORD RESEARCH/USD
|
|
|
(PQA2) Exploring the role of sarcopenia in obesity and breast cancer survival
|
5R01CA184953-03
|
$602,462
|
$602,462
|
CAAN, BETTE
|
KAISER FOUNDATION RESEARCH INSTITUTE
|
|
|
(PQA2) Interstitial stiffness as a physicochemical modulator of obesity-induced b
|
5R01CA185293-03
|
$329,112
|
$329,112
|
FISCHBACH, CLAUDIA
|
CORNELL UNIVERSITY
|
|
|
(PQA2) MAMMALIAN REGENERATION, HIGH FAT DIETS, AND BREAST CANCER: A COMMON LINK?
|
5R01CA180070-05
|
$339,116
|
$339,116
|
HEBER-KATZ, ELLEN
|
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
|
|
|
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause
|
5R01CA185530-03
|
$367,275
|
$367,275
|
MOSES, MARSHA
|
CHILDREN'S HOSPITAL CORPORATION
|
|
|
(PQA4) GPS exposure to environments & relations with biomarkers of cancer risk
|
4R01CA179977-04
|
$816,993
|
$408,497
|
KERR, JACQUELINE
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
|
(PQB-4) Opposing Effects of the SASP in Cancer Progression
|
5R01CA184572-03
|
$329,925
|
$108,875
|
HERBIG, UTZ
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
|
(PQB4) Stochastic Profiling of Functional Single-Cell States Within Solid Tumors
|
5R01CA194470-02
|
$464,569
|
$153,308
|
JANES, KEVIN
|
UNIVERSITY OF VIRGINIA
|
|
Total relevant funding to Breast for this search: $612,106,802
|
